Viking Therapeutics: Oral GLP-1/GIP Phase III Gets FDA Green Light, Monthly Dosing Data Could Reshape the Obesity Label
Jefferies Global Healthcare Conference, June 4, 2026 — Viking CEO Brian Lian lays out a pivotal 18-month catalyst calendar
Two findings from Viking Therapeutics' appearance at the Jefferies 2026 Global Healthcare Conference stand out as genuinely new information for investors: the FDA has explicitly agreed to let Viking skip directly from Phase II to Phase III for its oral GLP-1/GIP co-agonist — a rare regulatory shortcut that compresses the development timeline and cost materially — and the company's ongoing maintenance study could, if successful, feed reduced-frequency dosing arms directly into the already-running VANQUISH Phase III extension, a convergence of timelines that was not originally planned but could significantly differentiate the label.
FDA Blesses a Shorter Road for the Oral Program
The oral formulation of VK2735, Viking's dual GLP-1/GIP co-agonist, is heading into Phase III in the fourth quarter of this year without completing a traditional Phase III safety build-up on its own. The reason, as CEO Brian Lian explained, is that the subcutaneous Phase III program will generate safety data on approximately 6,000 patients — a dataset large enough that the FDA was willing to let Viking lean on it for the oral program. "The FDA pointed out risks going from Phase II to Phase III, but they were okay with it," Lian said.
The practical implications are significant. The oral Phase III trials will be roughly 75% smaller than the subcutaneous VANQUISH studies and will have a shorter titration period, meaning fewer weeks before the 52-week steady treatment phase begins. The net result is a program that is both cheaper and faster than a conventional path. For a company with 65 employees running four concurrent Phase III trials, that efficiency matters enormously. Lian was direct about the operational strain: "It's a heavy lift for a company our size to go into four different Phase III trials."
On timing, Lian described the oral program as roughly 12 to 18 months behind the subcutaneous data, which itself is expected in the second half of 2027. That would put oral Phase III readouts somewhere in the 2028-to-2029 window, though enrollment rates across the two studies could tighten or widen that gap.
Maintenance Study Could Reshape the Phase III Label in Real Time
Perhaps the most strategically interesting development disclosed at the conference is how Viking is positioning its maintenance dosing study — originally a standalone exploration of whether VK2735's 8-to-10-day half-life could support every-other-week or monthly injections — to feed directly into the VANQUISH long-term extension.
The maintenance study, initiated in the fourth quarter of 2025, is expected to report data in the third quarter of 2026. That timing lines up neatly with the one-year extension period of the VANQUISH trials, meaning that if the maintenance arms look attractive, Viking could incorporate two or three of them into the extension before the window closes. Lian acknowledged this was not the original design: "That wasn't the way we planned it, but that's just the way the timelines seem to be converging."
To take advantage of that convergence, Viking recently restructured the maintenance study, dropping three oral dosing arms and adding five new subcutaneous arms — two additional every-other-week arms and three monthly arms — in order to get a wider read on which regimens are worth bringing forward. The key outcome metric Lian described is whether patients transitioning to monthly dosing continue losing weight (even at a slower slope), flatline within roughly 5% of their transition weight, or rebound. A flatline or continued loss would be considered a success.
On tolerability, the primary concern is whether dropping to monthly high-dose injections reintroduces gastrointestinal side effects, particularly vomiting, that had faded during weekly titration. Lian's view is that the risk is low because patients will always have drug on board throughout the monthly interval — "it's not like you're going from zero to 60" — but acknowledged it is one of the study's key open questions. A vomiting rate that spikes back toward early-titration levels would be a meaningful negative signal.
Commercial Architecture Built Around Channels That Bypass the Rebate Wall
Chief Commercial Officer Neil Aubuchon made a pointed argument that the commercial landscape for obesity drugs has shifted enough to give a company Viking's size a credible path to meaningful market share without relying on traditional PBM access. He identified three channels — direct-to-consumer platforms, direct-to-employer programs, and Medicare starting July 1 — as collectively reducing the relevance of the rebate wall that has historically protected incumbent brands.
"These companies do direct-to-consumer marketing better than big pharma does," Aubuchon said of the telehealth and DTC platforms Viking is actively in discussions with. He noted that some larger players have stated that 50% of their business is now cash pay. On the employer side, Aubuchon described a carve-out structure where employers subsidize GLP-1 costs like a gym membership, with employees covering the remainder via HSA — again bypassing PBM infrastructure. On Medicare, he was measured but optimistic: "I do believe this will not be a duopoly."
Aubuchon also pointed to the commercial efficiency of having the same API in both the injectable and oral formulations under a single brand name. With the injectable launching first and the oral to follow, brand awareness built around the injectable should transfer directly, reducing the marketing spend required for the oral launch. "That allows you to not have to build that brand awareness among consumers and physicians," he said.
On the partnership question, Lian reiterated that Viking remains open to inbound interest but is actively preparing a standalone commercial infrastructure. The implicit message is that any deal would need to be on Viking's terms — the company is not running a process from a position of need.
Amylin Program: Early but Potent
Viking filed an IND for a novel amylin agonist earlier in the second quarter and is starting a single ascending dose study this month — June 2026. PK and tolerability data from the SAD study are expected late 2026 or early 2027, with multiple ascending dose data, which would include early weight loss signals, likely a 2027 event.
Lian described the compound as showing greater potency than VK2735 in head-to-head monkey studies at equivalent dose levels, with a near 1:1 balance between amylin-3 and calcitonin receptor activity and preclinical PK that suggests weekly dosing is feasible. He noted that the original thesis was to combine the amylin agonist with VK2735 to push efficacy toward best-in-class, but that the standalone commercial case has become more compelling as the market has evolved — particularly for patients at lower BMI thresholds or those with GLP-1 intolerance. It remains an early-stage program and the tolerability profile in humans is entirely unknown.
Balance Sheet: Funded Through the Critical Data Window
CFO Gregory Zante confirmed that Viking ended the first quarter of 2026 with over $600 million in cash, which the company believes is sufficient to fund through the subcutaneous Phase III top-line data in the second half of 2027 and into the early portion of 2028 — covering the oral Phase III initiation as well. The company's cost structure remains heavily weighted toward direct clinical trial expenses, which Zante characterized as a "very efficient cash spend footprint." Pre-commercial build costs are acknowledged but described as manageable within the current runway, with Aubuchon indicating he and Zante have stress-tested the commercial spend scenario and are comfortable with the current position.